32 results about "Neurologic Dysfunctions" patented technology

The invention provides a nerve regulation and control system and method for a spinal cord ventral epidural region, and the system employs a microprocessor to generate multiple paths of pulse width modulation signals, and drives a voltage-controlled current source after amplitude adjustment. Stimulation current with adjustable frequency, pulse width and amplitude is output to act on a spinal cord ventral nerve structure. Real-time monitoring of stimulation current of each channel is realized through combination of voltage sampling and a single-pole multi-throw analog switch, feedback information of a body position, myoelectricity, pressure and other multi-mode sensors is fused, a closed-loop control mechanism is constructed, and dynamic adjustment and individualized optimization of electrical stimulation parameters are realized. The system has the advantages of being more accurate in electrical stimulation positioning, more sensitive in response, more intelligent in control and the like, and is suitable for intelligent rehabilitation intervention in scenes of spinal cord injury, cerebral palsy, neurological dysfunction and the like.

An orally administered composition positively mitigates the progression of central nervous system diseases such as Alzheimer's, Parkinson's and Multiple Sclerosis. The composition consists of a lipid based blood brain barrier transport medium (Base Transport Sub-Formula) to which other elements (Functional Targeting Compound) may be integrated to mediate specific chemo-neurological dysfunction. It may be administered through the mouth as droplets a spray medium or a chewable tablet.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

The invention belongs to the technical field of biological medicines, and particularly relates to application of Chi3l1 as a target spot in preparation of a medicine for preventing or treating secondary brain injury after cerebral hemorrhage. By integrating space transcriptomics and a mononuclear RNA sequencing technology, the spatial heterogeneity and cell type specificity of gene expression in ICH afterbrain tissue are deeply analyzed, a group of astrocyte subgroups AST1 with neuritis existing around hematoma in the acute stage after cerebral hemorrhage is identified, Chi3l1 is determined as a key inflammatory effect factor of the AST1 subgroups, and the AST1 subgroups with neuritis are used as the key inflammatory effect factor of the AST1 subgroups. And the influence of the gene on the phenotypic transformation of astrocytes and microglial cells is verified. The discovery provides an important theoretical basis for developing a treatment strategy of targeting Chi3l1, and is expected to improve neuroinflammatory response and neurological dysfunction after ICH by regulating and controlling expression of the AST1 subgroup and Chi3l1, and opens up a new direction for treatment of ICH.

The invention relates to the technical field of new application of medicines, in particular to application of G15 to treatment of white matter injury based on promotion of cerebrovascular generation, and finds that the G15 has the effect of promoting cerebrovascular generation, can promote myelination insufficiency caused by hypoxia in the early development stage and can improve neurological dysfunction caused by hypoxia, and the G15 has the effect of promoting cerebrovascular generation. Moreover, myelin sheath regeneration of a local demyelination area after the adult can be promoted, so that the effect of directly treating the white matter injury from the pathological aspect is achieved. The invention provides a new application of G15 in treating white matter injury and long-term neurological dysfunction by promoting cerebrovascular generation.

Described herein are systems and methods used to evaluate individuals such as children for behavioral disorders, developmental delays, and neurological impairments. An exemplary method includes receiving input data of an individual related to a behavioral disorder, neurological impairment, or developmental delay, and evaluating the input data using an evaluation module comprising at least one machine learning model, thereby generating an evaluation result, where the machine learning model comprises one or more decision threshold hyperparameters that differentiate between a positive evaluation, negative evaluation, and an indeterminate evaluation with respect to a presence or an absence of the behavioral disorder, neurological impairment, or developmental delay.

The application provides a kinase inhibitor leading compound, a virtual screening method thereof and application of the kinase inhibitor leading compound in preparation of branched-chain alpha-keto acid dehydrogenase kinase inhibitors and / or drugs for treating diseases mediated by branched-chain alpha-keto acid dehydrogenase kinase. The virtual screening method provided by the application combines various virtual screening platforms to screen a large-scale compound library, improves the true positive rate of screening results, reduces the number of compounds needing experimental screening, and saves screening time and cost. In addition, the compounds I-III screened out with good binding affinity to BCKDK can be used in researches on targeting BCKDK to treat major diseases such as obesity, insulin resistance, maple syrup urine disease, neurological dysfunction, liver cancer, colorectal cancer and tumor cachexia.

The invention discloses application of a gene editing virus interfering expression and secretion of enzyme prototype cathepsin D in brain trauma, belongs to the field of gene functions and application, and finds that brain injury is aggravated and nerve dysfunction is aggravated due to the fact that the level of the enzyme prototype cathepsin D in plasma is increased due to the brain trauma through detection. The mechanism is as follows: the enzyme prototype cathepsin D enhances the transendocytosis effect of cerebral vascular endothelial cells after brain trauma, so that plasma inflammatory factors are gathered in damaged brain tissues; meanwhile, the expression of cerebrovascular endothelial cells VCAM-1 is also up-regulated, and neutrophil infiltration in an injured brain region after brain trauma is intensified. Research finds that down-regulation of plasma enzyme prototype cathepsin D can alleviate inflammatory factor concentration and neutrophil density in a brain injury area after trauma, and alleviate neurological function impairment of mice. Aiming at the functions of the plasma prototype cathepsin D, a strategy for reducing the plasma level of the plasma prototype cathepsin D by a gene editing technology for interfering the prototype cathepsin D is provided for treating the cerebral trauma.

The present invention addresses the problem of providing: a biomarker for determining cognitive impairment or nerve function disorder in an early stage with high accuracy; and others.　In the present invention, a drebrin metabolite peptide (iMADP) selected from the below-mentioned peptides (i) to (iii) is used as a biomarker for determining cognitive impairment or nerve function disorder. (i) A peptide comprising the amino acid sequence represented by SEQ ID NO: 4; (ii) a peptide comprising the amino acid sequence represented by SEQ ID NO: 5; and (iii) a peptide which comprises an amino acid sequence having a structure such that one or more amino acid residues are deleted, substituted, and / or added in the amino acid sequence represented by SEQ ID NO: 4 or SEQ ID NO: 5.

Systems and methods are provided for delivering closed-loop or partially closed-loop baroreflex activation therapy (BAT) to treat conditions associated with autonomic dysfunction. A pulse generator delivers stimulation while physiological data, such as ECG, heart rate variability, bioimpedance, and physical activity levels, is collected from one or more sensors. The data is analyzed to assess autonomic nervous system activity, and stimulation parameters are dynamically adjusted in response. In some embodiments, adjustments are made on a beat-to-beat basis using ECG input. Artificial intelligence algorithms may be used to predict patient-specific responses, optimize therapy, and evaluate effectiveness. The method may further include integrating patient-reported symptoms, wirelessly transmitting data, or adjusting stimulation duty cycle based on time of day. The system may further incorporate patient-reported symptoms, a clinician dashboard for remote monitoring, and a multi-channel lead. Stimulation may be delivered non-invasively or via an implantable device.

The application provides a kind of affected side spatial stratification activation and multi-modal unilateral spatial neglect (USN) cognitive function evaluation and training intelligent system, aiming at solving the pain points such as low efficiency of evaluation, training homogeneity, effect difficult to transfer in USN patient rehabilitation, and building a whole-process intelligent rehabilitation system of "accurate evaluation-personalized training-dynamic optimization-effect transfer". Through the combination of rapid quantitative evaluation system, behavior data and electroencephalogram signal, the objective grading of USN severity is realized, which gets rid of artificial dependence and greatly improves the evaluation efficiency and accuracy; through the whole-process automatic operation and machine learning self-adaptive optimization, the operation cost of clinical personnel is reduced, the rehabilitation effect is traceable and evaluable, and an accurate and personalized intelligent rehabilitation system is built, which provides a whole-process solution for USN patients and has important significance for promoting the intelligent development of post-stroke neurological dysfunction rehabilitation.

Long-acting glucagon like peptide 1 receptor agonists (GLP-1r agonists) reduce and inhibit pathological processes that give rise to long-term neurological impairment. A biotinylated and / or lipidated GLP-1r agonist analogs with enhanced enzymatic stability needed for gastrointestinal absorption, improved bioavailability and pharmacokinetics are described. In preferred embodiments, the GLP-1r agonist analogs have the amino acid sequence of any one of SEQ ID NOs: 9-35. The compositions are typically administered via oral or parenteral routes. The compositions are particularly suited for treating, alleviating, and / or preventing one or more neurological diseases or disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). Methods of treating a human subject having AD or PD or at risk of AD or PD are provided.

The invention discloses a construction method of a microglial cell conditional knock-down dynactin animal model, which comprises the following steps: selecting a Dctn1LoxP gene knock-in mouse, hybridizing the Dctn1LoxP gene knock-in mouse with a Cx3cr1-Cre transgenic mouse, and carrying out three rounds of breeding to obtain a genotype Dctn1LoxP / LoxP; a mouse of Cx3cr1-Cre; the expression of Cre recombinase is driven by a Cx3cr1 gene promoter, and the 2nd to 4th exons of the Dctn1 gene are cut, so that the knockout of p150Glue and the reduction of the protein levels of other subunits of dynactin are realized. The model is strong in specificity and high in knock-down efficiency, animals show microglial cell morphology abnormity and movement coordination function defects, the model can be used for researching the influence of dynactin on microglial cell neurobiological functions, and a reliable tool is provided for pathogenesis exploration and drug screening of related neurological dysfunction.

The application provides application of IL-17A as a target point in preparation of a drug for screening treatment or prevention of cardiac arrest. The application also provides application of IL-17A as a target point in preparation of a monoclonal antibody drug for screening treatment or prevention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving post-cardiac arrest syndrome. The application provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for early intervention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving myocardial injury, cardiac dysfunction, brain injury or neurological dysfunction caused by cardiac arrest. The application also provides application of a reagent for detecting IL-17A level in serum in preparation of a kit for detecting a myocardial infarction combined with cardiac arrest patient. The application proves by experiments that IL-17 related pathways in heart and brain tissues are significantly activated after cardiac arrest, and IL-17A in serum is significantly increased, and early antagonism of IL-17A by using an IL-17A monoclonal antibody after resuscitation can improve myocardial injury, cardiac dysfunction (systolic and diastolic dysfunction), brain tissue injury or neurological dysfunction after cardiac arrest, and improve survival rate after cardiac arrest.

The invention provides a method of determining whether a subject has a neurological dysfunction associated with a signal in a particular electroencephalogram (EEG) or magnetoencephalogram (MEG) frequency range, the method comprising: obtaining an EEG power spectrum from the subject; and obtaining a metric quantifying the magnitude of power in particular frequency range metric quantifying the power in the power spectrum in the particular frequency range, wherein the metric summarises the power in said frequency range corrected using an estimate of the power in said frequency range that is attributable to background signal that is specific to said frequency range, wherein the metric is indicative of the presence and / or severity and / or direction of a neurological dysfunction. Related methods and devices are also described.

The invention relates to the technical field of biological medicines, in particular to application of piperine in preparation of a medicine for treating cerebral ischemia-reperfusion injury and a verification method, and the application of the piperine in preparation of the medicine for treating cerebral ischemia-reperfusion injury is confirmed for the first time. It is shown that the piperine can be used for treating the new indications of the cerebral ischemic stroke reperfusion injury, the current experimental result provides powerful support and basis for wide application of the new indications of the piperine, and the treatment effect of the piperine on the cerebral ischemic reperfusion injury is evaluated; on a mouse cerebral ischemia reperfusion model, the piperine can reduce the volume of mouse cerebral infarction induced by cerebral ischemia reperfusion, relieve neurological dysfunction, increase cerebral blood flow, relieve brain injury and improve blood-brain barrier dysfunction, and the piperine is used for preparing the medicine for treating cerebral arterial thrombosis reperfusion injury. The invention develops a new medical application of piperine in treating cerebral ischemia-reperfusion injury.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating cerebral arterial thrombosis, and relates to the technical field of biological medicine. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 5-30 parts of Yulangsan, 5-30 parts of panax japonicus, 5-30 parts of ruta graveolens, 5-30 parts of camphorwood, 5-30 parts of millettia japonica, 5-30 parts of costus root, 5-30 parts of rhizoma curculiginis, 5-30 parts of clinopodium herb, 5-30 parts of white hyacinth bean and 5-30 parts of radix puerariae. The whole formula treats both qi and blood, regulates phlegm and blood stasis, is reasonable in compatibility of the medicines, and has the effects of tonifying qi and activating blood, dispersing blood stasis and dredging collaterals, clearing heat and dissipating blood stasis, restoring consciousness and dredging collaterals, and tonifying spleen and warming kidney. The traditional Chinese medicine composition can relieve cerebral infarction and encephaledema, improve neurological dysfunction, inhibit neuronal apoptosis and regulate inflammatory response to relieve inflammatory damage of brain tissue, and a good treatment effect on cerebral arterial thrombosis model rats is achieved. The traditional Chinese medicine composition provides a new choice for development of medicines for treating cerebral arterial thrombosis.

The present application provides a nerve regulation system and method for the ventral epidural region of the spinal cord, wherein the nerve regulation system for the ventral epidural region of the spinal cord generates a multi-channel pulse width modulation signal by using a microprocessor, drives a voltage-controlled current source after amplitude adjustment, and outputs a stimulation current with adjustable frequency, pulse width and amplitude to act on the ventral nerve structure of the spinal cord. Real-time monitoring of the stimulation current of each channel is realized by combining voltage sampling and single-pole multi-throw analog switches, while the feedback information of multiple modal sensors such as body position, electromyography and pressure is integrated to construct a closed-loop control mechanism, realize dynamic adjustment and individual optimization of the electric stimulation parameters. The precise activation ability of motor and autonomic nerve function is enhanced, and the present application has the advantages of more accurate electric stimulation positioning, more sensitive reaction, more intelligent control and the like, and is suitable for intelligent rehabilitation intervention in scenes such as spinal cord injury, cerebral palsy, and nerve dysfunction.

One variation of a method for modeling neurological development includes: aggregating electroencephalography (EEG) data that comprise multiple EEG signals of each user in a set of users, EEG signals of each user recorded on multiple distinct dates, the set of users comprising a plurality of users of various known neurological statuses; identifying a synchronization pattern trend within the EEG data of the set of users; and correlating the synchronization pattern trend with neurological development within the set of users.

The invention relates to the technical field of medical animal disease models, in particular to a method for establishing a gene point mutation non-human primate model.According to the method, editing is conducted through a CRISPR / Cas9 gene editing system, and finally a non-human primate model carrying CHD8c.3724Cgt is obtained; according to the cynomolgus monkey with T (p.Arg1242Ter) point mutation, different types of point mutations occur at the 3724th basic group of the CHD8 gene, the mutation of T enables arginine (Arg) at the 1242nd site to be replaced by a termination codon to form truncated protein, so that the dosage of CHD8 protein haploid coded by the gene is insufficient. The animal model for simulating human CHD8 mutation related nervous system diseases is constructed and can be used as an ideal research model for researching autism related phenotypes caused by insufficient haplodose, and a foundation is laid for revealing a neurological dysfunction mechanism and exploring a potential treatment strategy.

One variation of a method for modeling neurological development includes: aggregating electroencephalography (EEG) data that comprise multiple EEG signals of each user in a set of users, EEG signals of each user recorded on multiple distinct dates, the set of users comprising a plurality of users of various known neurological statuses; identifying a synchronization pattern trend within the EEG data of the set of users; and correlating the synchronization pattern trend with neurological development within the set of users.

The invention provides a traditional Chinese medicine composition for promoting neural function recovery, an AnnaoPingchong pill and a preparation method of the AnnaoPingchong pill. The traditional Chinese medicine composition comprises the following active ingredient raw materials in parts by weight: 25-40 parts of raw fossil fragments, 25-40 parts of raw oysters, 10-25 parts of radix cyathulae, 5-18 parts of tribulus terrestris, 8-20 parts of uncaria rhynchophylla, 8-18 parts of rhizoma alismatis, 10-20 parts of moutan bark, 10-20 parts of cape jasmine, 8-25 parts of scutellaria baicalensis, 10-25 parts of radix paeoniae alba, 5-15 parts of raw rhubarb, 3-12 parts of liquorice, 1-5 parts of lotus plumule, 0.1-0.5 part of calculus bovis factitius and 0.01-0.05 part of artificial borneol. The traditional Chinese medicine composition follows the medication principle of'monarch, minister, assistant and guide 'of traditional Chinese medicines, can lower qi, quiet qi and blood and calm vitality, and has a good treatment effect on neurological dysfunction after cerebral hemorrhage.

The inventors found that BIND, psychiatric diseases with jaundice and psychiatric diseases caused by UGT1A1 gene mutation of a subject can be treated, prevented or controlled by administering a 5-HT1A / 1B receptor agonist to the subject. Therefore, the present disclosure provides a pharmaceutical composition, including a 5-HT1A / 1B receptor agonist, for the treatment, prevention or control of BIND, psychiatric disorders with jaundice, and psychiatric disorders caused by UGT1A1 gene mutation.

The present invention relates to a Chinese medicine composition for treating ischemic stroke, and a method and application thereof, and belongs to the technical field of traditional Chinese medicine. The Chinese medicine composition for treating ischemic stroke disclosed in the present invention comprises the following raw materials: ginseng, Panax notoginseng, processed Polygonum multiflorum, Chuanxiong, safflower, salvia miltiorrhiza, hawthorn, mistletoe, epimedium, kudzu root, buffalo horn, ginseng leaf, calamus, and borneol. In the present invention, Chuanxiong is fermented with a composite bacteria consisting of Lactobacillus plantarum, Bacillus subtilis, and Acoriformis scabra, so that more laccase and active substances are produced in the fermentation product. The fermentation product is then treated with the composite enzyme, and the Chuanxiong obtained by the treatment has better medicinal efficacy, thereby enhancing the therapeutic effect of the Chinese medicine composition for treating ischemic stroke, significantly alleviating neurological dysfunction caused by cerebral ischemia, and having a good protective effect on neurological damage caused by ischemic stroke.

The APRIL study demonstrated that infusion of ApTOLL 0.2 mg / kg (SEQ ID NO: 1) in combination with endovascular treatment in selected stroke patients was safe and reduced mortality at 90 days. ApTOLL was demonstrated to limit the occurrence of intracranial hemorrhage and reperfusion injury that can occur after recanalization, and also improve early neurological dysfunction and long-term disability. The ApTOLL molecule is provided for use in reducing the risk of intracranial hemorrhage or secondary hemorrhage, reducing neurological damage, and improving neurological recovery after acute ischemic stroke in subjects.

The invention discloses an application of a pro-CTSD inhibitor or antibody in cerebral arterial thrombosis, belongs to the technical field of gene functions and application, and discloses an application of pro-CTSD as a therapeutic target in screening a biological preparation for treating secondary inflammation of cerebral arterial thrombosis. The invention finds that pro-CTSD can aggravate the phenomena of brain injury and neurological dysfunction by enhancing the adhesion effect of cerebral vascular endothelial cells. The invention also finds that by down-regulating the plasma pro-CTSD level, the cerebral injury of the cerebral arterial thrombosis can be alleviated, the neurological dysfunction is improved, and an effective therapeutic target is provided for developing the cerebral arterial thrombosis.

The application provides a flexible adherable implantable multi-site precise electrical stimulation system and a preparation method thereof, and belongs to the technical field of flexible electrode preparation. The application comprises a flexible substrate and a package, which is internally printed with a continuous stretchable liquid metal gallium-indium conductor; double-sided adhesive hydrogel with double-interface chemical modification, which is covalently adhered to the flexible packaging material and biological tissue respectively; an external electrical stimulation conductor connected with the liquid metal gallium-indium conductor, and the liquid metal conductive network contains stimulation sites that can precisely stimulate different segments of the ventral and dorsal spinal cord. The application first combines the double-network hydrogel with covalent bonding effect with the flexible electrode prepared based on liquid metal gallium-indium, realizes stable adhesion of the double-interface of the flexible electrode and the tissue, greatly improves the long-term implantation stability, can realize precise stimulation of the ventral and dorsal bilateral multi-site of the epidural spinal cord, and provides a new instrument support for the treatment of spinal cord-related neurological dysfunction.

The application of β-asarone ether in the preparation of drugs for promoting myelin regeneration, for improving neurological dysfunction in organisms with myelin injury, inhibiting inflammatory demyelination in the central nervous system, and enhancing memory and cognitive function.

The invention relates to a compound, in particular to a medicine for treating cranial nerve dysfunction diseases, namely alpha-asarone and an isomer beta-asarone, the molecular formula is C12H16O3, the molecular weight is 208.26, the Chinese name is 2, 4, 5-trimethoxy-1-propenyl benzene, and a preparation prepared from the alpha-asarone and the isomer beta-asarone can be used for treating cranial nerve dysfunction diseases. The pharmaceutical composition is used for treating various memory, cognition, sensory integration and thinking function partial or all deficiency diseases caused by cranial nerve dysfunction, including Alzheimer's disease, dementia, encephalitis sequelae, cerebral palsy, children intellectual development disorder, autism, hyperactivity and the like.

The invention discloses a non-invasive cerebrospinal fluid flow regulation and control device based on gait and sacral pillow rhythm collaborative simulation, and relates to the technical field of medical instruments. The invention aims to solve the ubiquitous problems of high invasiveness, high infection risk, single regulation and control mode, lack of intelligent feedback mechanism and the like in the treatment means of cerebrospinal fluid flow disorder. Complete non-invasive contact is achieved, cerebrospinal fluid is mildly promoted to flow in a rhythm simulation mode, and infection and injury risks are remarkably reduced; 'gait-sacrum alternating rhythm 'and'occipital bone-respiratory rhythm' are creatively combined and are close to natural cerebrospinal fluid circulation dynamics; rhythm optimization is carried out based on real-time physiological data, and closed-loop regulation and control of intelligent intervention and dynamic correction are achieved. The device is not only suitable for neurological dysfunctions such as postoperative hydrocephalus and cerebral concussion, but also can be popularized to the fields of cognitive training, elderly rehabilitation, sleep intervention and the like; and a data acquisition and analysis module is embedded, so that the system can be used as a cerebrospinal fluid dynamics research platform or a medical teaching training tool.